15-Dec-2025
Analysts Are Bullish on Top Healthcare Stocks: Certara (CERT), Sera Prognostics (SERA)
TipRanks (Sun, 14-Dec 12:40 PM ET)
Sera Announces Publication Acceptance for PRIME Study
PRNewswire (Mon, 24-Nov 8:00 AM ET)
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
Business Wire (Thu, 20-Nov 4:15 PM ET)
SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
PRNewswire (Thu, 13-Nov 4:05 PM ET)
PRNewswire (Thu, 30-Oct 4:05 PM ET)
Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer
PRNewswire (Wed, 1-Oct 8:05 AM ET)
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Sera Prognostics - Class A trades on the NASDAQ stock market under the symbol SERA.
As of December 15, 2025, SERA stock price declined to $3.38 with 173,829 million shares trading.
SERA has a beta of 1.32, meaning it tends to be more sensitive to market movements. SERA has a correlation of 0.03 to the broad based SPY ETF.
SERA has a market cap of $130.45 million. This is considered a Micro Cap stock.
Last quarter Sera Prognostics - Class A reported $16,000 in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-72,000 and exceeded earnings estimates by $.04.
In the last 3 years, SERA traded as high as $12.36 and as low as $1.10.
The top ETF exchange traded funds that SERA belongs to (by Net Assets): VTI, VXF, IWC, AVSC, MSSM.
SERA has underperformed the market in the last year with a return of -60.8%, while SPY returned +13.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SERA shares. However, SERA has outperformed the market in the last 3 month and 2 week periods, returning +9.0% and +5.3%, while SPY returned +3.3% and +0.1%, respectively. This indicates SERA has been having a stronger performance recently.
SERA support price is $3.27 and resistance is $3.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SERA shares will trade within this expected range on the day.